When is EW's latest earnings report released?
The most recent financial report for Edwards lifesciences corporation (EW) covers the period of 2026Q1 and was published on 2026/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EW's short-term business performance and financial health. For the latest updates on EW's earnings releases, visit this page regularly.
Where does EW fall in the P/E River chart?
According to historical valuation range analysis, Edwards lifesciences corporation (EW)'s current price-to-earnings (P/E) ratio is 30.46, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of EW?
According to the latest financial report, Edwards lifesciences corporation (EW) reported an Operating Profit of 514.7M with an Operating Margin of 31.22% this period, representing a growth of 30.37% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is EW's revenue growth?
In the latest financial report, Edwards lifesciences corporation (EW) announced revenue of 1.65B, with a Year-Over-Year growth rate of 16.7%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does EW have?
At the end of the period, Edwards lifesciences corporation (EW) held Total Cash and Cash Equivalents of 2.94B, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does EW go with three margins increasing?
In the latest report, Edwards lifesciences corporation (EW) achieved the “three margins increasing” benchmark, with a gross margin of 78.21%%, operating margin of 31.22%%, and net margin of 23.09%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EW's profit trajectory and future growth potential.
Is EW's EPS continuing to grow?
According to the past four quarterly reports, Edwards lifesciences corporation (EW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.66. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of EW?
Edwards lifesciences corporation (EW)'s Free Cash Flow (FCF) for the period is 353.5M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 299.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of EW?
The latest valuation data shows Edwards lifesciences corporation (EW) has a Price-To-Earnings (PE) ratio of 30.46 and a Price/Earnings-To-Growth (PEG) ratio of 0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
